

7. (Amended) A method according to claim 4, which comprises the administration of 8 to 12 mg of Compound (I).

8. (Amended) A method according to claim 5, which comprises the administration of 2 mg of Compound (I).

9. (Amended) A method according to claim 5, which comprises the administration of 4 mg of Compound (I).

10. (Amended) A method according to claim 6, which comprises the administration of 8 mg of Compound (I).

11. (Amended) A pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I), insulin and a pharmaceutically acceptable carrier therefor.

13. (Amended) A composition according to claim 11, which comprises up to 12 mg or 2 to 12 mg of Compound (I).


REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicants have amended the claims to put them in conformity with the U.S. practice.

No new matter has been introduced.

Respectfully submitted,


Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5073

n:\yps\response\p31831C1\preamd.doc

FOOTNOTES

Sub
A2
Cont

Sub
A3